Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSupportive Therapy, ToxicityProtocol groupComplicationsPlasma cell neoplasmsTransplantationDiseaseMultiple MyelomaOsteolysisStem Cell mobilizationStem Cell Transplantation, AutologousSubgroupBCL2 expression highBRAF V600-MutationCast nephropathyPlasma cell leukemiaSmoldering Myelomat(11;14)ICD10C90.-C90.0-M89.5-Z94.80MeSHHematopoietic Stem Cell MobilizationLeukemia, Plasma CellMultiple MyelomaOsteolysisPlasmacytomaTransplantation, AutologousSequenceALCYONE: BORT1.3/DRTM(8/8/16)/MELP9/PRED60, MM, C1 (PID1433) -|- C2-9 (PID651) -|- C10+ (PID461)ALCYONE: BORT1.3/DRTM16/MELP9/PRED60, MM, C1 (PID588) -|- C2-9 (PID651) -|- C10+ (PID461)ALCYONE: BORT1.3/DRTM1800/MELP9/PRED60, MM, C1 (PID1617) -|- C2-9 (PID1618) -|- maint. (PID1619)AQUILA: DRTM1800, MM, Smoldering, C1-2 (PID2790) -|- C3-6 (PID2791) -|- C7+ (PID2792)ASPIRE: CARF(20/27)/LENA25/DEXA40, MM, C1 (PID522) -|- C2-12 (PID523) -|- C13-18 (PID524) -|- Maint., MM (PID525)AURIGA: DRTM1800/LENA10, MM, maint. according to ASCT, C1-2 (PID2796) -|- C3-6 (PID2797) -|- C7+ (PID2798)BELLINI: VNTC800/BORT1,3/DEXA20, MM, C1-8 (PID1790) -|- VNTC800/BORT1,3/DEXA20, MM, C9+ (PID1791)BEND90/BORT1,3/PRED60, MM, C1 (PID1550) -|- BEND90/BORT1,3/PRED60, MM, C2-9 (PID1551)BORT1,3/PANO20/DEXA20, MM, C1-8 (PID611) -|- BORT1,3/PANO20/DEXA20, MM, C9-16 (PID612)BORT1.3/MELP9/PRED60, MM C1 (PID1003) -|- C2-5 (PID1004) -|- maint. (PID1005)BORT1.3/PGLDX30/DEXA40, MM, C1 (PID1963) -|- C2 (PID1964) -|- C3 (PID1963) -|- C4 (PID1964) -|- Cons. (PID1965)BORT1.5/CYCL300/DEXA40, MM, C1-2 (PID1852) -|- BORT1.5/CYCL300/DEXA40, MM, C3-4 (PID1853)CANDOR: DRTM1800/CARF(20/56)/DEXA(20/20), MM, C1 (PID2152) -|- C2 (PID2330) -|- C3-6 (PID2153) -|- C7+ (PID2154)CARF(20/27)/POMA4/DEXA40, MM, C1 (PID1586) -|- C2-6 (PID1587) -|- C7+ (PID1588)CARF(20/36)/CYCL300/DEXA40, MM, C1 (PID1455) -|- C2-9 (PID1456) -|- Maint. (PID1457)CARF(20/36)/CYCL300/DEXA40, MM, C1, var. 1 (PID1458) -|- C2-9 (PID1459) -|- maint. (PID1457)CARF(20/70)/DRTM(8/8/16)/DEXA(20/20), MM, C1 (PID1438) -|- C2 (PID1439) -|- C3-6 (PID1440) -|- C7+ (PID1441)CARF70/CYCL300/DEXA40, MM (PID1741) -|- CARF70/CYCL300/DEXA40 - CARF70 maint., MM (PID1742)CASSIOPEIA: BORT1.3/DRTM(8/8/16)/THAL100/DEXA40, MM, C1 (PID1482) -|- C2 (PID1483) -|- C3-4 (PID1484) -|- Cons. (PID1485) -|- maint. (PID1486)CASSIOPEIA: BORT1.3/DRTM1800/THAL100/DEXA40, MM, C1-2 (PID1628) -|- C3-4 (PID1629) -|- Cons. (PID1630) -|- maint. (PID1635)CASTOR: BORT1.3/DRTM(8/8/16)/DEXA(20/20), MM, C1 (PID1432) -|- C2-3 (PID818) -|- C4-8 (PID819) -|- C9+ (PID820)CASTOR: BORT1.3/DRTM16/DEXA(20/20), MM, C1 (PID817) -|- C2-3 (PID818) -|- C4-8 (PID819) -|- C9+ (PID820)CASTOR: BORT1.3/DRTM1800/DEXA(20/20), MM, C1-3 (PID1613) -|- C1-8 (PID1614) -|- maint. (PID1615)CENTAURUS: DRTM(8/8/16), MM, smoldering, C1 (PID1556) -|- C2-3 (PID2123) -|- C4-7 (PID2124) -|- C8-20 (PID2125)CEPHEUS: DRTM1800/BORT1.3/LENA25/DEXA20, MM, C1-2, var. 1 (PID2979) -|- C3-8 (PID2980) -|- C9+ (PID2981)DREAMM-7: BELAMA2,5/BORT1,3/DEXA20, MM, Z1-8 (PID3174) -|- BELAMA2,5, Z9+ (PID3175)DREAMM-8: BELAMA2,5/POMA4/DEXA40, MM, Z1 (PID2674) -|- BELAMA1,9/POMA4/DEXA40, Z2+ (PID2675)DRTM(8/8/16)/CARF(20/36)LENA25/DEXA20, MM, C1 (PID2579) -|- C2 (PID2580) -|- C3-6 (PID2581) -|- C7 (PID2582) -|- C8-10 (PID2583) -|- Maint. (PID2584)DRTM(8/8/16)/POMA4/DEXA(20/20), MM, C1 (PID1435) -|- C2 (PID1223) -|- C3-6 (PID1224) -|- C7+ (PID1225)DRTM16/POMA4/DEXA(20/20), MM, C1 (PID1222) -|- C2 (PID1223) -|- C3-6 (PID1224) -|- C7+ (PID1225)DRTM1800/POMA4/DEXA(20/20), MM, C1-2 (PID1993) -|- C3-6 (PID1994) -|- C7+ (PID1995)Elo-KRdELOQUENT2ELOQUENT3: ELOT10/POMA4/DEXA28, MM, C1+2 (PID1227) -|- ELOT20/POMA4/DEXA28, MM, C3+ (PID1229)EMN09 trialENDEAVOR: CARF(20/56)/DEXA20, MM, C1 (PID733) -|- CARF56/DEXA20, MM, C2+ (PID734)GMMG-HD7GRIFFINICARIA-MM: ISAT10/POMA4/DEXA40, MM, C1 (PID1716) -|- ISAT10/POMA4/DEXA40, MM, C2+ (PID1717)IFM 2009/DETERMINATION: BORT1.3/LENA25/DEXA20, Ind., MM (PID1036) -|- cons. after ASCT (PID1040) or cons. without ASCT (PID1037) -|- maint. after ASCT (PID891) or maint. (PID2181)IKEMA: ISAT10/CARF(20/56)/DEXA20, MM, C1 (PID1808) -|- ISAT10/CARF56/DEXA20, MM, C2+ (PID1809)IMROZ: BORT1.3/ISAT10/LENA25/DEXA20, MM, Ind., C1 (PID2660) -|- C2-4 (PID2661) -|- C5-17 (PID2662) -|- C18+ (PID2663)IXAZ4/CYCL300/DEXA40, MM, C1-9 (PID2411) -|- IXAZ4, maint., C1+ (PID2410)LINKER-MM1LYRA: DRTM1800/BORT1.5/CYCL300/DEXA(20/20), MM, C1-2 (PID1941) -|- C3-6 (PID1942) -|- C7-8 (PID1943) -|- Maint. (PID1944)MagnetisMM-3: ELRA(12/32/76), MM, C1 (PID2537) -|- C2-6 (PID2538) -|- C7+ (PID2539)MAIA: DRTM(8/8/16)/LENA25/DEXA(20/20), MM, C1, first line (PID1436) -|- C2 (PID1437) -|- C3-6 (PID1337) -|- C7+ (PID1338)MAIA: DRTM16/LENA25/DEXA(20/20), MM, C1, first line (PID1333) -|- C2 (PID1437) -|- C3-6 (PID1337) -|- C7+ (PID1338)MAIA: DRTM1800/LENA25/DEXA(20/20), MM, C1-2, first line (PID1625) -|- C3-6 (PID1626) -|- C7+ (PID1627)MajesTEC-1: TECL(0.06/0.3/1.5), MM, Z1 (PID2391) -|- TECL1.5, Z2+ (PID2392)MajesTEC-3: TECL(0.06/0.3/1.5)/DRTM1800, MM, C1 (PID3085) -|- C2 (PID3086) -|- C3-6 (PID3087) -|- MM, C7+ (PID3088)MM-015: MPR-R (MELP0,18/PRED2/LENA10), Ind., MM, A (PID518) -|- MPR-R (MELP0,18/PRED2/LENA10) - LENA 10 maint., MM, B (PID520)MonumenTAL-1: TALQ(0.01/0.06/0.4), MM, C1 (PID2469) -|- TALQ0.4, C2+ (PID2470)MonumenTAL-1: TALQ(0.01/0.06/0.4/0.8), MM, C1 (PID2467) -|- TALQ0.8, C2+ (PID2468)MonumenTAL-3MUK five protocol: CARF(20/36)/CYCL500/DEXA40, MM, second line, C1 (PID1460) -|- C2-6 (PID1461) -|- C7-12 (PID1462) -|- C13-24 (PID1463)OPTIMISMM: BORT1,3/POMA4/DEXA20, MM, C1-8 (PID1591) -|- BORT1,3/POMA4/DEXA20, MM, C9+ (PID1592)PERSEUS: DRTM1800/BORT1.3/LENA25/DEXA40, MM, Ind., C1-2 (PID2516) -|- C3-4 (PID2517) -|- C5-6 (PID2518) -|- Maint. (PID2519)POLLUX: DRTM(8/8/16)/LENA25/DEXA(20/20), MM, C1 (PID1434) -|- C2 (PID814) -|- C3-6 (PID815) -|- C7+ (PID816)POLLUX: DRTM16/LENA25/DEXA(20/20), MM, C1 (PID813) -|- C2 (PID814) -|- C3-6 (PID815) -|- C7+ (PID816)RedirecTT-1: TECL(0.06/0.3/1.5)/TALQ(0.01/0.06/0.4), MM, C1 (PID2962) -|- C2-7 (PID2963) -|- C8+ (PID2964)SIRIUS: DRTM(8/8/16), MM, C1 (PID1431) -|- C2 (PID746) -|- C3-6 (PID745) -|- C7+ (PID747)SIRIUS: DRTM16, MM, C1 (PID744) -|- C2 (PID746) -|- C3-6 (PID745) -|- C7+ (PID747)SIRIUS: DRTM1800, MM, C1-2 (PID1622) -|- C3-6 (PID1623) -|- C7+ (PID1624)STUDY-GMMG-HD6 (arm A1): BORT1.3/LENA25/DEXA20, MM, Ind. A1 + A2, C1-2 (PID797) -|- C3-4 (PID800) -|- Cons. (PID801) -|- maint. C1-6 (PID1094) -|- maint. C7+ (PID1095)STUDY-GMMG-HD6 (arm A2): BORT1.3/LENA25/DEXA20, MM, Ind. A1 + A2, C1-2 (PID797) -|- C3-4 (PID800) -|- Cons. (PID802) -|- maint. C1-6 (PID1092) -|- maint. C7+ (PID1093)STUDY-GMMG-HD6 (arm B1): BORT1.3/LENA25/DEXA20/ELOT10, MM, Ind. B1 + B2, C1-2 (PID798) -|- C3-4 (PID799) -|- Cons. (PID801) -|- maint. C1-6 (PID1094) -|- maint. C7+ (PID1095)STUDY-GMMG-HD6 (arm B2): BORT1.3/LENA25/DEXA20/ELOT10, MM, Ind. B1 + B2, C1-2 (PID798) -|- C3-4 (PID799) -|- Cons. (PID802) -|- maint. C1-6 (PID1092) -|- maint. C7+ (PID1093)UNITO-EMN10 (IBd): IXAZ4/BEND75/DEXA40, MM, C1-9 (PID2409) -|- IXAZ4, maint., C1+ (PID2410)VISTA: BORT1,3/MELP9/PRED60, MM C1-4 (PID533) -|- BORT1,3/MELP9/PRED60, MM C5-9 (PID534)ChemotherapyChemo-substanceBelantamab MafodotinBendamustineBinimetinibBortezomibCarfilzomibCisplatinCyclophosphamideDaratumumabDexamethasoneDoxorubicinDoxorubicin pegylated liposomalElotuzumabElranatamabEncorafenibEtoposideIsatuximabIxazomibLenalidomideLinvoseltamabMelphalanMelphalan flufenamideNaCl 0.9%PanobinostatPomalidomidePrednisoloneSelinexorTalquetamabTeclistamabThalidomideVenetoclaxChemo-substanceBelantamab MafodotinBendamustineBinimetinibBortezomibCarfilzomibCisplatinCyclophosphamideDaratumumabDexamethasoneDoxorubicinDoxorubicin pegylated liposomalElotuzumabElranatamabEncorafenibEtoposideIsatuximabIxazomibLenalidomideLinvoseltamabMelphalanMelphalan flufenamideNaCl 0.9%PanobinostatPomalidomidePrednisoloneSelinexorTalquetamabTeclistamabThalidomideVenetoclaxChemo-substanceBelantamab MafodotinBendamustineBinimetinibBortezomibCarfilzomibCisplatinCyclophosphamideDaratumumabDexamethasoneDoxorubicinDoxorubicin pegylated liposomalElotuzumabElranatamabEncorafenibEtoposideIsatuximabIxazomibLenalidomideLinvoseltamabMelphalanMelphalan flufenamideNaCl 0.9%PanobinostatPomalidomidePrednisoloneSelinexorTalquetamabTeclistamabThalidomideVenetoclaxChemo-substanceBelantamab MafodotinBendamustineBinimetinibBortezomibCarfilzomibCisplatinCyclophosphamideDaratumumabDexamethasoneDoxorubicinDoxorubicin pegylated liposomalElotuzumabElranatamabEncorafenibEtoposideIsatuximabIxazomibLenalidomideLinvoseltamabMelphalanMelphalan flufenamideNaCl 0.9%PanobinostatPomalidomidePrednisoloneSelinexorTalquetamabTeclistamabThalidomideVenetoclaxNo. Substances1234578 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDalteparinDenosumabDexamethasoneDimetindenFamotidineFilgrastimFosaprepitantFurosemideGranisetronHyaluronic acidLevofloxacinMagnesium sulfateMelphalanMesnaMethylprednisoloneMontelukastNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPlerixaforPotassium chloridePrednisolonePyridoxineValaciclovirZoledronic AcidSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDalteparinDenosumabDexamethasoneDimetindenFamotidineFilgrastimFosaprepitantFurosemideGranisetronHyaluronic acidLevofloxacinMagnesium sulfateMelphalanMesnaMethylprednisoloneMontelukastNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPlerixaforPotassium chloridePrednisolonePyridoxineValaciclovirZoledronic AcidSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDalteparinDenosumabDexamethasoneDimetindenFamotidineFilgrastimFosaprepitantFurosemideGranisetronHyaluronic acidLevofloxacinMagnesium sulfateMelphalanMesnaMethylprednisoloneMontelukastNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPlerixaforPotassium chloridePrednisolonePyridoxineValaciclovirZoledronic AcidSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDalteparinDenosumabDexamethasoneDimetindenFamotidineFilgrastimFosaprepitantFurosemideGranisetronHyaluronic acidLevofloxacinMagnesium sulfateMelphalanMesnaMethylprednisoloneMontelukastNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPlerixaforPotassium chloridePrednisolonePyridoxineValaciclovirZoledronic AcidNo. Substances123456789101112Protocol classificationTherapy classificationalternativecurrent standardformer alternativestudy analogStudy protocol, currentIntensityhigh doseHochdosis, myeloablativ, bei autologer SZT (MA)Low doseStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapySecond lineseveral possibleThird line Therapy phaseautologous stem cell transplantationConsolidationInductionMaintenanceTherapy intentioncurativedisease controlpalliativesupportiveRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaAtrial FibrillationBleedingBone PainCardiotoxicityCataractConstipationCOVID-19 infectionCytokine Release SyndromeDepressionDiarrheaDyspneaEdemaEmbolismEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHerpes ZosterHypercalcemiaHyperglycemiaHyperhidrosisHypertensionHypertriglyceridemiaHypocalcemiaHypogammaglobulinemiaHypoglycemiaHypokalemiaHyponatremiaHypophosphatemiaHypotensionIncrease AminotransferasesIncrease Creatinine PhosphokinaseInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisMyalgiasNail ChangesNauseaNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOsteonecrosis of the JawPainPneumoniaPneumonitisPyrexiaQTc Time ExtensionRashRenal FailureSepsisTaste disturbanceThrombocytopenia below 50 000/µlThromboembolic EventTumor Lysis SyndromeUpper Respiratory Tract InfectionVisual DisturbancesVomiting only studiesPublicationAuthorAttal MBadros AZBaz RBenboubker LBringhen ABringhen SBrown SBumma NChari ACohen ACohen YCCorso ACosta LJDerman BADimopoulos MDimopoulos MAFacon TGay FGiesen N Goldschmidt HGrosicki SHarousseau JHungria VKaufman JLKnauf WKrishnan AKumar SKLakshman ALandgren COLee CKLentzsch SLesokhin AM Leypoldt LBLonial SLudwig HMateos MMcCarthy PMina RMoreau PMorgan GJOrlowski RZPalumbo APaseo de San Vicente, Salamanca, Spain, ALCYONE trialPönisch WRaje NReeder CBRichardson PRichardson PGRoyer BSan-Miquel JFSan Miguel JFSchjesvold FHShah JSonneveld PStewart AKTouzeau C Usmani SZVoorhees PMWeisel KYimer HDiseaseAuto-SZT beim MMfortschreitendes oder wiederkehrendes MM, Stadium I - IIIMM, Erstlinie, > 65 JahreMM, refraktär, mindestens 2 Vortherapien (u.a. Bortezomib, Lenalidomid, Alkylanz)MM, rezidiviert oder therapierefraktär, ECOG 0-2MM, symptomatisch, nicht zur SZT geeignet aufgrund Komorbiditäten oder älter als 65 JahreMM, symptomatisch, nicht zur Transplantation geeignet, älter als 65 JahreMM, symptomatisch, nicht zur Transplantation geeignet oder über 65 Jahre, ErstlinieMM mit Therapieindikation, 18 - 65 Jahre, ECOG 0-3 (3 nur wenn durch Myelom bedingt), ErstlinieMM mit Therapieindikation, neudiagnostiziert, ECOG 0-2MM Rezidiv, 1-3 VortherapienMM Stadium II und III, 18 - 65 Jahre, ECOG 0-3 (3 nur wenn durch Myelom bedingt), ErstlinieMultiples Myelom, 1-3 Vortherapielinien, ECOG 0-2multiples Myelom, 1-3 Vortherapien, inkl. IMIDs und Proteasom-Inhibitor, ECOG 0-2Multiples Myelom, 1-3 Vortherapien, inkl. Proteosominhibitor, ECOG 0-2Multiples Myelom, 65 J. oder älter und/oder nicht-transplantationsfähig, ECOG 0-2Multiples Myelom, 65 J. oder älter und/oder nicht-transplantationsfähig, rezidiviert oder therapierefraktär, ECOG 0-2Multiples Myelom, ASCT-geeignet, 18 - 70 Jahre, ECOG 0-2Multiples Myelom, ASCT-geeignet, 18-70 Jahre, ECOG 0-2Multiples Myelom, ASCT-ungeeignet, ECOG 0-2Multiples Myelom, BCL2-Expression hoch oder t(11;14), rezidiviert oder refraktär, 1-3 Vortherapien, PI sensitiv oder naiv, ECOG 0-2Multiples Myelom, dreifach refraktär, ECOG 0-2Multiples Myelom, Drittlinie oder spätere, ECOG 0-2Multiples Myelom, Drittlinie oder Spätere, ECOG 0-2Multiples Myelom, ECOG 0-1Multiples Myelom, ErstdiagnoseMultiples Myelom, Erstdiagnose, Hoch-Risiko Zytogenetik, ECOG 0-2, transplantationsfähigMultiples Myelom, Erstdiagnose, Hoch-Risiko Zytogenetik, ECOG 0-2, transplantfähigmultiples Myelom, Erstdiagnose nach Induktionstherapie und autologer Transplantation, ECOG 0-1multiples Myelom, Erstlinie, < 70 Jahre, ECOG 0-3Multiples Myelom, Erstlinie, > 65 Jahremultiples Myelom, Erstlinie, transplantationsfähig, ECOG 0-2Multiples Myelom, Erstlinie, transplant ungeeignet, ECOG 0-2multiples Myelom, Hochdosis-Therapie möglich, Erstlinie, ECOG 0-2Multiples Myelom, Hochrisiko (del17p, t(4;14) oder t(14;16) oder >3 Kopien von 1q21) und ISS Stadium II oder IIIMultiples Myelom, Hochrisiko (del17p, t(4;14) oder t(14;16) or >3 Kopien von 1q21) und ISS Stadium II oder IIIMultiples Myelom, Induktionstherapie vor ASCT nach mindestens 2 Zyklen StandardtherapieMultiples Myelom, mindestens 1 Vortherapie, aber keine Anti-CD38 und/oder Anti-BCMA-Therapiemultiples Myelom, mindestens 2 Vortherapien, und Resistenz gegen Lenalidomid und Proteasom-InhibitorMultiples Myelom, mindestens eine Vortherapie, ECOG 0-1Multiples Myelom, mindestens eine Vortherapie, ECOG 0-2Multiples Myelom, nach Induktionstherapie und autologer Transplantation, VGPR, MRD+, ECOG 0-2Multiples Myelom, neu diagnostiziert oder rezidiviert, ECOG 0-2multiples Myelom, Rezidiv, 1-3 VortherapienMultiples Myelom, rezidivierend oder refrakrär nach Lanalidomid, 1-5 Vortherapien, ECOG 0-2Multiples Myelom, rezidiviert oder therapierefraktär, mind. 2 vorherige Therapielinien, BRAF V600E MutationMultiples Myelom, rezidiviert oder therapierefraktär, mind. 2-4 Vortherapien, inkl. Lenalidomid und Proteosominhibitor, ECOG 0-2Multiples Myelom, Rezidiv nach 1-3 VortherapienMultiples Myelom, Rezidivtherapiemultiples Myelom, Rezidivtherapie nach Proteasomeninhibitor und Immunmodulator, ECOG 0-2Multiples Myelom, t(11;14), rezidiviert oder refraktär, nach Vortherapie mit PI, IMiD und anti-CD38-Antikörper, ECOG 0-1Multiples Myelom mit Cast-NephropathieNeudiagnostiziertes, multiples Myelom, Erstlinie in Kombination mit der Induktion und als Erhaltung für alle PatientenNeudiagnostiziertes, unbehandeltes multiples Myelom, ECOG 1-4neudiagnostiziertes MM, nicht zur Transplantation geeignet oder über 65 Jahre, ECOG 0-2neudiagnostiziertes multiples Myelom, < 65 JahreNeu diagnostiziertes multiples Myelom, nach autologer Stammzelltransplantation, < 65 JahreNeu diagnostiziertes multiples Myelom, nicht-transplantationsfähig, ECOG 0-2neudiagnostiziertes multiples Myelom, nicht geeignet für Hochdosis + ASZT, ECOG 0-2Neu diagnostiziertes multiples Myelom, Stadium II oder III oder progredientes Stadium I nach Durie and Salmon, transplantationsfähigNeu diagnostiziertes multiples Myelom, transplantationsfähig, ECOG 0-2neu diagnostiziertes multiples Myelom mit mind. einer lytischen KnochenläsionNicht transplantationsfähige Patienten mit neu diagnostiziertem multiplen Myelom, über 65 Jahre, ECOG 0-2Nicht transplantationsfähige Patienten mit rezidiviertem oder therapierefraktärem multiplen Myelom, über 65 Jahre, ECOG 0-2Plasmazell-Leukämie, Erstlinie, ECOG 0-3Refraktäres oder rezidiviertes multiples Myelom, ECOG 0-2, 1-3 Vortherapienrefraktäres oder rezidiviertes multiples Myelom, ECOG 0-2, 1-3 Vortherapienrefraktäres oder wiederkehrendes multiples Myelom, 1-3 Vortherapien, ECOG 0-2Refraktäres oder wiederkehrendes Multiples Myelom, 2.-4. Linie, ECOG 0-2refraktäres oder wiederkehrendes multiples Myelom, ECOG 0-2, 1-3 Vortherapienrezidivierendes oder refraktäres multiples Myelom, 1-3 Vortherapien, ECOG 0-2rezidivierendes oder refraktäres multiples Myelom, Drittlinie oder Spätere, ECOG 0-2rezidivierendes oder refraktäres Myelom, Drittlinie refraktär auf Lenalidomid, ECOG 0-2 Rezidiviertes oder refraktäres (triple-class exposure) multiples Myelom Rezidiviertes oder refraktäres multiples MyelomRezidiviertes oder refraktäres multiples Myelom, ECOG 0-2Rezidiviertes oder refraktäres multiples Myelom, mind. 1 lenalidomidhaltige VortherapieRezidiviertes oder therapierefraktäres multiples Myelom, mindestens 1 Vortherapie (inkl. Lenalidomid), ECOG 0-2Rezidivtherapie des multiplen Myeloms, 1-3 VortherapienRezidivtherapie des multiplen Myeloms, mindestens 2 VortherapienSchwelendes Myelom, hoch-Risiko, ECOG 0-1Schwelendes Myelom, intermediär- oder hoch-Risiko, asymptomatischSchwelendes Myelom, intermediär- oder hoch-Risiko, ECOG 0-1Symptomatisches multiples Myelom, für ASCT nicht geeignet, mind. partielle Remission 6-12 Monate nach Standardtherapie, ECOG 0-2Symptomatisches multiples Myelom, nicht ASCT geeignetwiederkeherendes oder refraktäres Myelom, mindestens Zweitlinie nach Lenalidomid, ECOG 0-2wiederkehrendes oder refraktäres multiples Myelomwiederkehrendes oder refraktäres multiples Myelom, Stadium I,II,III, ECOG 0-2wiederkehrendes oder refraktäres multiples Myelom, Stadium I-IIIwiederkehrendes oder refraktäres Myelom, mindestens Zweitlinie nach Lenalidomid, ECOG 0-2OriginAlexandra General Hospital, National and Kapodistrian University of Athens, Athens, AQUILA trialAzienda Ospedaliero-Universitaria Citt `a della Salute e della Scienza di Torino, ItalyBMT Program, Roswell Park Cancer Institute, Buffalo, NY, CALGB 100104Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, USACenter of Oncology and Hematology, Wilhelminenspital, Vienna, AustriaCentre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, France, IMROZ trialCentre René Gauducheau,Nantes/St. Herblain, IFM2005-01Centrum Haematologie and Onkologie Bethanien, Frankfurt, Germany, GMMG trialCentrum Hämatologie and Onkologie Bethanien, Frankfurt, Germany, GMMG trialClinica Universidad de Navarra-CIMA, Pamplona, Spain, PANORAMA1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, OPTIMISMM trialDepartment of Hematology, Clinical Oncology and Hemostasiology, University of Leipzig, GermanyDepartment of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Germany, PERSPECTIVE trial, German-speaking Myeloma Multicenter Group (GMMG)Department of Hematology, University of Turin, Italy, CASTORDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CADepartment of Hematology and Medical Oncology, WInship Cancer Institute, Atlanta, ELOQUENT-2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, MonumenTAL-3 trialDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, SIRIUSDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TXDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLDepartment of Medicine, Wilhelminenspital, Vienna, AustriaDivision of Hematology and Oncology, University of Alabama at Birmingham, MajesTEC-3 TrialDivision of Hematology and Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, USAEmory University, Atlanta, USAErasmus MC Cancer Institute, Rotterdam, the Netherlands, PERSEUS TrialGerman-Speaking Myeloma Multicenter Group, GMMG-HD6German-Speaking Myeloma Multicenter Group, GMMG-HD7GMMG MM5 StudieHarvard Medical School, Boston, MA, USA, OPTIMISMM trialHeidelberg University Hospital, Heidelberg, Germany, GMMG-BIRMA trialHematology Clinic, University Hospital Hotel-Dieu, Nantes, MajesTEC-1 trialHospital e Instituto Biosanitario de Salamanca (IBSAL), Universidad de Salamanca (IBMCC/CSIC), SpainHOVON-65/GMMG-HD4 StudieIFm2009 / Determination trialInstituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, DREAMM-7 trialInstitut Universitaire du Cancer de Toulouse-Oncopole and Service d'Epidemiologie, Centre Hospitalier et Universitaire de Toulouse, Toulouse, FranceInstitut Universitaire du Cancer de Toulouse-Oncopole and Service d’Epidémiologie, Toulouse, IFM 2009 StudyInstitut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ICARIA-MMLeeds Institute of Clinical Trials Research, University of Leeds, UK, Phase 2 Muk Five StudyLevine Cancer Institute, Atrium Health, Charlotte, GRIFFIN trialMateos MMayo Clinic, Rochester, MinnesotaMayo Clinic, Rochester, USA, BELLINI trialMayo Clinic, Scottsdale, USAMedical University of Silesia, Katowice, Poland, BOSTON trialMemorial Sloan Kettering Cancer Center, New York, NY, USA, CEPHEUS trialMemorial Sloan Kettering Cancer Center, New York, USA, CENTAURUS trialMemorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York City, NY, USA, MagnetisMM-3 trialMount Sinai School of Medicine, New York, MonumenTAL-1 trialMRC Myelom IX StudieMyeloma Unit, Division of Hematology, University of Torino, IST-CAR-561National and Kapodistrian University Athens School of Medicine, Athens, Greece, CANDOR trialNational and Kapodistrian University of AthensNational and Kapodistrian University of Athens, Greece, DREAMM-8 trialNational and Kapodistrian University of Athens, School of Medicine, Athens, Greece, TOURMALINE-MM4 TrialOncotherapeutics, West Hollywood, USAOslo University Hospital, Oslo, Norway, OCEAN trialPaseo de San Vicente, Salamanca, Spain, ALCYONE trialPoliclinico S. Matteo, University of Pavia, ItalyRoyal Marsden Hospital, London, UKRoyal Marsden NHS Foundation Trust, London, UKSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ENDEAVORSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece, POLLUXTel Aviv Sourasky Medical Center and the Faculty of Medical and Health Sciences, Tel Aviv University, RedirecTT-1 trialTexas Oncology-Tyler, US Oncology Research, Tyler, USA, LYRA studyThe ASPIRE Investigators, ASPIRE StudieThe Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide (FIRST) Trial Team, First StudieThe MM-015 InvestigatorsThe Ohio State University Comprehensive Cancer Center, Columbus, OH, LINKER-MM1 trialThe University of Arkansas for Medical Sciences, Little RockThe University of Texas, MD Anderson Cancer Center, Houston, Texas, USAThe VISTA Trial InvestigatorsTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, USA, STORM trialTisch Cancer Institute, Mount Sinai School of Medicine, New YorkTisch Cancer Institute, Mount Sinai School of Medicine, New York, NYUniversity Hospital, Amiens, France, Intergroupe Francophone du Myélome.University Hospital, Amiens, France; Intergroupe Francophone du Myélome.University hospital, Nantes, FranceUniversity Hospital, Nantes, France, IFM2013-04 trialUniversity Hospital, Nantes, France, IKEMA trialUniversity Hospital Heidelberg, Heidelberg, Germany, GMMG-HD7University Hospital Hôtel-Dieu, Nantes, France, CASSIOPEIAUniversity Hospital Hôtel Dieu, Nantes, TOURMALINE-MM1 Study GroupUniversity Hospital of Salamanca, Salamanca, SpainUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany, GMMG-CONCEPT trialUniversity of Chicago Medical Center, Chicago, IllinoisUniversity of Lille, Centre Hospitalier Universitaire (CHU) Lille, MAIA trialUniversity of Maryland, Baltimore, Maryland, United States, AURIGA studyUniversity of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy, UNITO-EMN10 trialUniversity of Torino, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza, Torino, Italy, EMN09 trialWinship Cancer Institute of Emory University, Atlanta, Georgia, USAProtokolle in Überarbeitung 256 protocols foundAURIGA - Daratumumab 1800 / Lenalidomide 10, multiple myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 1-2 (PID2796 V1.1)AURIGA - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 3-6 (PID2797 V1.1)AURIGA - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 7+ (PID2798 V1.1)Revision: Belantamab Mafodotin 1,9 / Pomalidomid 4 / Dexamethason 40, multiples Myelom, Zyklus 2+ (PID2675 V1.1)Revision: Belantamab Mafodotin 2,5 / Pomalidomid 4 / Dexamethason 40, multiples Myelom, Zyklus 1 (PID2674 V1.1)Bendamustine 60 / Bortezomib 1.3 / Prednisolone 100, Multiple Myeloma (PID615 V1.2)Bendamustine 70 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma (PID740 V1.1)Bendamustine 75 / Lenalidomide 10 / Dexamethasone 40, Multiple Myeloma (PID2397 V1.0)Bendamustine 90 / Bortezomib 1.3 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1550 V1.1)Bendamustine 90 / Bortezomib 1.3 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID1551 V1.1)Bortezomib 1.0 / Doxorubicin 9 / Dexamethasone 40, Multiple Myeloma (PID2428 V1.0)Bortezomib 1.3 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2.4 (PID1964 V1.0)Bortezomib 1.3 / Cyclophosphamide 900 / Dexamethasone 40, Multiple Myeloma (PID532 V1.2)Bortezomib 1.3 / Daratumumab (8/8/16) / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1432 V1.1)Bortezomib 1.3 / Daratumumab (8/8/16) / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1433 V1.1)Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20) - Daratumumab 16 maintenance, Multiple Myeloma, Cycle 9+ (PID820 V1.1)Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID817 V2.1)Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2-3 (PID818 V1.2)Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 4-8 (PID819 V1.2)Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60 - Daratumumab 16 maintenance, Multiple Myeloma, Cycle 10+ (PID461 V1.1)Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, cycle 1 (PID588 V2.1)Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID651 V1.2)Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20) - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1615 V1.2)Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1-3 (PID1613 V1.1)Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20), Multiple Myeloma, Cycle 4-8 (PID1614 V1.2)Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60 - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1619 V1.2)Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1617 V1.2)Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID1618 V1.2)Bortezomib 1.3 / Dexamethasone 40, Induction, Multiple Myeloma (PID1164 V1.0)Bortezomib 1.3 / Doxorubicin 9 / Dexamethasone 40, Multiple Myeloma (PID529 V1.2)Bortezomib 1.3 / Lenalidomide 15 / Dexamethasone 40, Multiple Myeloma, consolidation (PID1965 V1.0)Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Consolidation without transplantation, Multiple Myeloma (PID1037 V1.2)Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Multiple Myeloma, Consolidation after Autologous Stem Cell Transplantation. (PID1040 V1.2)Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Induction, Multiple Myeloma (PID1036 V1.1)Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1003 V1.1)Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1-4 (PID533 V1.1)Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-5 (PID1004 V1.1)Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 5-9 (PID534 V1.1)Bortezomib 1.3 / Panobinostat 20 / Dexamethasone 20, Multiple Myeloma, Cycle 1-8 (PID611 V1.2)Bortezomib 1.3 / Panobinostat 20 / Dexamethasone 20, Multiple Myeloma, Cycle 9-16 (PID612 V1.2)Bortezomib 1.3 / Doxorubicin Pegylated Liposomal 30 / Dexamethasone 40, Multiple Myeloma, Cycle 1.3 (PID1963 V1.0)Bortezomib 1,3 / pegylated liposomal Doxorubicin 30, Multiple Myeloma (PID1589 V1.1)Bortezomib 1.3 / Pomalidomide 4 / Dexamethasone 20 , Multiple Myeloma, Cycle 9+ (PID1592 V1.1)Bortezomib 1.3 / Pomalidomide 4 / Dexamethasone 20, Multiple Myeloma, Cycle 1-8 (PID1591 V1.1)Bortezomib 1.3 / Prednisolone 60, maintenance, Multiple Myeloma (PID1005 V1.1)Bortezomib 1.3 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma (PID2427 V1.0)Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, cycle 1-2 (PID1852 V1.1)Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, cycle 3-4 (PID1853 V1.0)CAD - Cyclophosphamide 1000 / Doxorubicin 15 / Dexamethasone 40, stem cell mobilization, Multiple Myeloma (PID530 V1.0)Carfilzomib (20/27) / Bendamustine 70 / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID2406 V1.0)Carfilzomib (20/27) / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 1 (PID522 V1.2)Carfilzomib (20/27) / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma Cycle 1 (PID1586 V1.1)Carfilzomib (20/36) / Cyclophosphamide 300 / Dexamethasone 40 , Multiple Myeloma, Cycle 1, Variant 1 (PID1458 V1.1)Carfilzomib (20/36) / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 1 (PID1455 V1.1)Carfilzomib (20/36) / Cyclophosphamide 500 / Dexamethasone 40, Multiple Myeloma, second line, cycle 1 (PID1460 V1.1)Carfilzomib (20/56) / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID733 V1.0)Carfilzomib (20/70) / Daratumumab (8/8/16) / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1438 V1.1)Carfilzomib 27 / Bendamustine 70 / Dexamethasone 20 - Carfilzomib 27 / Dexamethasone 20, Multiple Myeloma, Maintenance, Cycle 9+ (PID2408 V1.0)Carfilzomib 27 / Bendamustine 70 / Dexamethasone 20, Multiple Myeloma, Cycle 2-8 (PID2407 V1.0)Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40 - Lenalidomide 25 / Dexamethasone 40, maintenance, Multiple Myeloma (PID525 V1.1)Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 13-18 (PID524 V1.1)Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 2-12 (PID523 V1.1)Carfilzomib 27 / Pomalidomide 4 / Dexamethasone 20, Multiple Myeloma, Cycle 7+ (PID1588 V1.1)Carfilzomib 27 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma Cycle 2-6 (PID1587 V1.1)Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma (PID1457 V1.0)Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2-9 (PID1456 V1.1)Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2-9, Variant 1 (PID1459 V1.1)Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma, second line, C13-24 (PID1463 V1.0)Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma, second line, cycle 7-12 (PID1462 V1.1)Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40, Multiple Myeloma, second line, cycle 2-6 (PID1461 V1.1)Carfilzomib 56 / Dexamethasone 20, Multiple Myeloma, Cycle 2+ (PID734 V1.0)Carfilzomib 70 / Cyclophosphamide 300 / Dexamethasone 40 - Carfilzomib 70 Maintenance, Multiple Myeloma (PID1742 V1.0)Carfilzomib 70 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma (PID1741 V1.0)Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2 (PID1439 V1.1)Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6 (PID1440 V1.1)Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID1441 V1.1)CASSIOPEIA - Bortezomib 1.3 / Daratumumab (8/8/16) / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma, Cycle 1 (PID1482 V1.3)CASSIOPEIA - Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone (40/20), multiple myeloma, cycle 3-4 (PID1484 V1.2)CASSIOPEIA - Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone 20, Multiple Myeloma, consolidation (PID1485 V1.3)CASSIOPEIA - Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone 40, multiple myeloma, cycle 2 (PID1483 V1.3)CASSIOPEIA - Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone 20 / Thalidomide 100 - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1635 V1.2)CASSIOPEIA - Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone (40/20), multiple myeloma, cycle 3-4 (PID1629 V1.2)CASSIOPEIA - Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone 20, Multiple Myeloma, consolidation (PID1630 V1.2)CASSIOPEIA - Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone 40, multiple myeloma, cycle 1-2 (PID1628 V1.2)CASSIOPEIA - Daratumumab 16, maintenance after Bortezomib 1.3 / Daratumumab 16 / Dexamethasone 20 / Thalidomide 100, Multiple Myeloma (PID1486 V1.1)CEPHEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 1-2 (PID2979 V1.1)CEPHEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 3-8 (PID2980 V1.1)CEPHEUS - Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, Cycle 9+ (PID2981 V1.1)Cyclophosphamide 500 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma (PID2264 V1.0)Cyclophosphamide 500 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma (PID2532 V1.0)Cyclophosphamide 500 / Thalidomide 50 / Dexamethasone 20, Multiple Myeloma (PID2533 V1.0)Daratumumab (8/8/16) / Carfilzomib (20/36) / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID2579 V1.0)Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1434 V1.2)Daratumumab (8/8/16) / Pomalidomide 4 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1435 V1.1)Daratumumab (8/8/16), Multiple Myeloma, Smoldering, Cycle 1 (PID1556 V2.0)Daratumumab (8/8/16), Multiple Myeloma, Cycle 1 (PID1431 V1.0)Daratumumab 16 / Carfilzomib (20/56) / Lenalidomide 15 / Dexamethasone 40, Multiple Myeloma, Cycle 7 (PID2582 V1.0)Daratumumab 16 / Carfilzomib 36 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 2 (PID2580 V1.0)Daratumumab 16 / Carfilzomib 36 / Lenalidomide 25 / Dexamethasone 20, multiple Myeloma, cycle 3-6 (PID2581 V1.0)Daratumumab 16 / Carfilzomib 56 / Lenalidomide 25 / Dexamethasone 40 - Daratumumab 16 / Lenalidomide 10, multiple Myeloma, maintenance (PID2584 V1.0)Daratumumab 16 / Carfilzomib 56 / Lenalidomide 25 / Dexamethasone 40, multiple Myeloma, cycle 8-10 (PID2583 V1.0)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID813 V3.1)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2 (PID814 V1.2)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6 (PID815 V1.2)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID816 V1.2)Daratumumab 16 / Pomalidomide 4 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1222 V2.1)Daratumumab 16 / Pomalidomide 4 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2 (PID1223 V2.1)Daratumumab 16 / Pomalidomide 4 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID1225 V2.1)Daratumumab 16 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma, Cycle 3-6 (PID1224 V2.1)Daratumumab 16, Multiple Myeloma Cycle 3-6 (PID745 V1.0)Daratumumab 16, Multiple Myeloma, Smoldering, cycle 2-3 (PID2123 V1.0)Daratumumab 16, Multiple Myeloma, Smoldering, cycle 4-7 (PID2124 V1.0)Daratumumab 16, Multiple Myeloma, Smoldering, cycle 8-20 (PID2125 V1.0)Daratumumab 16, Multiple Myeloma, Cycle 1 (PID744 V2.0)Daratumumab 16, Multiple Myeloma, Cycle 2 (PID746 V1.0)Daratumumab 16, Multiple Myeloma, Cycle 7+ (PID747 V1.0)Daratumumab 1800 / Carfilzomib (20/56) / Dexamethasone (20/20), Multiple Myeloma, Cycle 1. (PID2152 V1.1)Daratumumab 1800 / Carfilzomib 56 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2. (PID2330 V1.0)Daratumumab 1800 / Carfilzomib 56 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6 (PID2153 V1.0)Daratumumab 1800 / Carfilzomib 56 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID2154 V1.0)Daratumumab 1800 / Pomalidomide 4 / Dexamethasone (20/20), Multiple Myeloma, cycle 1-2 (PID1993 V1.0)Daratumumab 1800 / Pomalidomide 4 / Dexamethasone (20/20/40), Multiple Myeloma, cycle 3-6 (PID1994 V1.0)Daratumumab 1800 / Pomalidomide 4 / Dexamethasone (20/20/40), Multiple Myeloma, cycle 7+ (PID1995 V1.0)Daratumumab 1800, Multiple Myeloma, Smoldering, Cycle 1-2 (PID2790 V1.0)Daratumumab 1800, Multiple Myeloma, Smoldering, Cycle 3-6 (PID2791 V1.0)Daratumumab 1800, Multiple Myeloma, Smoldering, Cycle 7+ (PID2792 V1.0)Daratumumab 1800, Multiple Myeloma, Cycle 1-2 (PID1622 V1.0)Daratumumab 1800, Multiple Myeloma, Cycle 3-6 (PID1623 V1.0)Daratumumab 1800, Multiple Myeloma, Cycle 7+ (PID1624 V1.0)DCEP - dexamethasone 40 / cyclophosphamide 400 / etoposide 40 / cisplatin 10, multiple myeloma (PID1472 V1.3)Denosumab 120, multiple myleoma (PID1163 V1.0)Revision: DREAMM-7 - Belantamab Mafodotin 2,5 / Bortezomib 1,3 / Dexamethason 20 - Belantamab Mafodotin 2,5, multiples Myelom, Zyklus 9+ (PID3175 V1.1)Revision: DREAMM-7 - Belantamab Mafodotin 2,5 / Bortezomib 1,3 / Dexamethason 20, multiples Myelom, Zyklus 1-8 (PID3174 V1.1)DTPACE (Dexamethasone 40 / Thalidomide 400 / Cisplatin 10 / Doxorubicin 10 / Cyclophosphamide 400 / Etoposide 40), Multiple Myeloma (PID1471 V1.4)DTPACE/BORT - Bortezomib 1.0 / Dexamethasone 40 / Thalidomide 200 / Cisplatin 10 / Doxorubicin 10 / Cyclophosphamide 400 / Etoposide 40), Multiple Myeloma (PID1966 V1.2)Elo-KRd - Elotuzumab 10 / Carfilzomib (20/56)/ Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 1 (PID2398 V1.0)Elo-KRd - Elotuzumab 10 / Carfilzomib 70 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 2 (PID2399 V1.0)Elo-KRd - Elotuzumab 10 / Carfilzomib 70 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 9-12 (PID2401 V1.0)Elo-KRd - Elotuzumab 10 / Carfilzomib 70 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, Cycle 3-8 (PID2400 V1.0)ELOQUENT-2 - Elotuzumab 10 / Lenalidomide 25 / Dexamethasone (28/40), Multiple Myeloma Cycle 3+ (PID702 V1.4)ELOQUENT-2 - Elotuzumab 10 / Lenalidomide 25 / Dexamethasone 28, Multiple Myeloma Cycle 1-2 (PID701 V1.4)ELOQUENT-3 - Elotuzumab 10 / Pomalidomide 4 / Dexamethasone 28, Multiple Myeloma Cycle 1-2 (PID1227 V1.4)ELOQUENT-3 - Elotuzumab 20 / Pomalidomide 4 / Dexamethasone 28, Multiple Myeloma Cycle 3+ (PID1229 V1.4)Elranatamab (12/32/76), multiple myeloma, cycle 1 (PID2537 V1.1)Elranatamab 76, multiple myeloma, cycle 2-6 (PID2538 V1.0)Elranatamab 76, multiple myeloma, cycle 7+ (PID2539 V1.0)Encorafenib 450 / Binimetinib 45, Multiple Myeloma (PID2653 V1.0)GRIFFIN - Bortezomib 1.3 / Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 1 (PID1718 V1.2)GRIFFIN - Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 2-4 (PID1719 V1.2)GRIFFIN - Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, consolidation, cycle 5-6 (PID1720 V1.2)GRIFFIN - Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 1-4 (PID1723 V1.2)GRIFFIN - Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 20, multiple Myeloma, consolidation cycle 5-6 (PID1724 V1.2)GRIFFIN - Daratumumab 16 / Lenalidomide 10, Multiple Myeloma, maintenance (PID1721 V1.3)GRIFFIN - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance (PID1725 V1.3)Revision: HD 7 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 1-3 (PID40 V1.1)Revision: HD 7 - Lenalidomide 10 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 1 (PID43 V1.1)Revision: HD 7 - Lenalidomide 10, multiple myeloma, maintenance, cycle 2-3 (PID44 V1.1)Revision: HD 7 - Lenalidomide 15, multiple myeloma, maintenance, cycle 4+ (PID37 V1.1)HD7 - Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 1 (PID41 V1.2)HD7 - Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 2-3 (PID42 V1.2)HD7 - Lenalidomide 10 / Dexamethasone 20 / Isatuximab 10, Multiple Myeloma, maintenance, cycle 1 (PID45 V1.2)HD7 - Lenalidomide 10 / Isatuximab 10, multiple myeloma, maintenance, cycle 2-3 (PID46 V1.2)HD7 - Lenalidomide 15 / Isatuximab 10, multiple myeloma, maintenance, cycle 4+ (PID38 V1.2)High dose Cyclophosphamide 2000 for stem cell mobilization, Multiple Myeloma (PID535 V1.0.1)IMROZ - Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle (PID2660 V1.1)IMROZ - Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 2-4 (PID2661 V1.1)IMROZ - Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 18+ (PID2663 V1.1)IMROZ - Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 5-17 (PID2662 V1.1)Isatuximab 10 / Carfilzomib (20/56) / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID1808 V1.1)Isatuximab 10 / Carfilzomib (20/56) / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, Induction, Cycle 1 (PID2206 V1.0)Isatuximab 10 / Carfilzomib 45 / Lenalidomide 15 / Dexamethasone 40, Multiple Myeloma, consolidation, cycle 7 (PID2261 V1.0)Isatuximab 10 / Carfilzomib 56 / Dexamethasone 20, Multiple Myeloma, Cycle 2+ (PID1809 V1.1)Isatuximab 10 / Carfilzomib 56 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, Induction, Cycle 2-6 (PID2207 V1.0)Isatuximab 10 / Carfilzomib 56 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, consolidation, cycle 8-10 (PID2262 V1.0)Isatuximab 10 / Carfilzomib 70 / Lenalidomide 15, Multiple Myeloma, maintenance, cycle 1-26 (PID2263 V1.0)Isatuximab 10 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma, Cycle 1 (PID1716 V1.1)Isatuximab 10 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma, Cycle 2+ (PID1717 V1.1)Ixazomib 3, Multiple Myeloma, Maintenance (PID2189 V1.0)Ixazomib 4 / Bendamustine 75 / Dexamethasone 40, Multiple Myeloma, Cycle 1-9 (PID2409 V1.0)Ixazomib 4 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 1-9 (PID2411 V1.0)Ixazomib 4 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma (PID835 V1.1)Ixazomib 4 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma (PID1378 V1.1)Ixazomib 4, Multiple Myeloma, maintenance, cycle 10+ (PID2410 V1.0)Lenalidomide 10, Multiple Myeloma, maintenance (PID2181 V1.0)Lenalidomide 10, Multiple Myeloma, Maintenance after Autologous Stem Cell Transplantation, Autologous (PID891 V1.1)Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma (PID521 V1.1)Lenalidomide 25, Multiple Myeloma, Smoldering (PID1544 V1.0)Linvoseltamab (5/25), multiple myeloma, cycle 1 (PID2957 V1.0)Linvoseltamab 200, multiple myeloma, cycle 2 (PID2958 V1.0)Linvoseltamab 200, multiple myeloma, cycle 3 (PID2959 V1.0)Linvoseltamab 200, multiple myeloma, cycle 4 (PID2967 V1.0)Linvoseltamab 200, multiple myeloma, cycle 5-7 (PID2960 V1.0)Linvoseltamab 200, multiple myeloma, cycle 8+ (PID2961 V1.0)LYRA - Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20) - Daratumumab 1800 / Dexamethasone 12, Multiple Myeloma, maintenance (PID1944 V1.1)LYRA - Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1-2 (PID1941 V1.1)LYRA - Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 3-6 (PID1942 V1.1)LYRA - Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 7-8 (PID1943 V1.1)MAIA - Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone (20/20), multiple myeloma, cycle 1, first line (PID1436 V1.3)MAIA - Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, cycle 1, first line (PID1333 V2.3)MAIA - Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, cycle 2, first line (PID1437 V1.3)MAIA - Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), multiple myeloma, cycle 3-6, first line (PID1337 V2.3)MAIA - Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), multiple myeloma, cycle 7+, first line (PID1338 V2.3)MAIA - Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, cycle 1-2, first line (PID1625 V1.2)MAIA - Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20/40), multiple myeloma, cycle 3-6, first line (PID1626 V1.2)MAIA - Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20/40), multiple myeloma, cycle 7+, first line (PID1627 V1.2)Melphalan 0.18 / Prednisolone 2 / Lenalidomide 10 - Lenalidomide 10 maintenance, Multiple Myeloma, Part B (PID520 V1.0)Melphalan 0.18 / Prednisolone 2 / Lenalidomide 10, induction, Multiple Myeloma, part A (PID518 V1.1)Revision: Melphalan 100, multiples Myelom, autologe Stammzelltransplantation (PID528 V2.3)Melphalanflufenamide 40 / Dexamethasone 40, Multiple Myeloma (PID2757 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab (0.01/0.06/0.4/0.8), Multiple Myeloma, cycle 1 (PID3236 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab 0.8 / Dexamethasone 40, Multiple Myeloma, Cycle 2 (PID3237 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab 0.8 / Dexamethasone 40, Multiple Myeloma, cycles 3–4 (PID3238 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab 0.8 / Pomalidomide 2 / Dexamethasone 40, Multiple Myeloma, cycle 2 (PID3241 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab 0.8 / Pomalidomide 2 / Dexamethasone 40, Multiple Myeloma, cycles 3–4 (PID3242 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab 0.8 / Pomalidomide 2, Multiple Myeloma, cycles 5–6 (PID3243 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab 0.8 / Pomalidomide 2, Multiple Myeloma, cycle 7+ (PID3244 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab 0.8, Multiple Myeloma, cycles 5–6 (PID3239 V1.0)MonumenTAL-3 - Daratumumab 1800 / Talquetamab 0.8, Multiple Myeloma, cycle 7+ (PID3240 V1.0)pegylated liposomal Doxorubicin 5 / Pomalidomide 3 / Dexamethasone 40, Multiple Myeloma (PID1590 V1.1)PERSEUS - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance (PID2519 V1.1)PERSEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, multiple myeloma, induction, cycle 1-2 (PID2516 V1.1)PERSEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, multiple myeloma, induction, cycle 3-4 (PID2517 V1.1)PERSEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, multiple myeloma, consolidation, cycle 5-6 (PID2518 V1.1)Pomalidomide 4 / Cyclophosphamide 400 / Dexamethasone 40, Multiple Myeloma (PID57 V1.1)Pomalidomide 4 / Cyclophosphamide 400 / Dexamethasone 40, Multiple Myeloma, Variant 1 (PID53 V1.1)Pomalidomide 4 / Cyclophosphamide 500 / Dexamethasone 40, Multiple Myeloma (PID1226 V1.1)Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma (PID122 V1.1)Selinexor 100 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma (PID1795 V1.0)Selinexor 80 / Dexamethasone 20, Multiple Myeloma (PID1792 V1.0)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Elotuzumab 10, Multiple Myeloma, Induction, Cycle 1-2 (PID798 V1.1)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Elotuzumab 10, Multiple Myeloma, Induction, Cycle 3-4 (PID799 V1.1)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Elotuzumab 10, Multiple Myeloma, consolidation (PID802 V1.1)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 1-2 (PID797 V1.0)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 3-4 (PID800 V1.0)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, consolidation (PID801 V1.0)Study - GMMG-HD 6 - Lenalidomide 10 / Dexamethasone 12 / Elotuzumab 10, Multiple Myeloma, Maintenance Cycle 1-6 (PID1092 V1.1)Study - GMMG-HD 6 - Lenalidomide 10 / Dexamethasone 12, Multiple Myeloma, Maintenance Cycle 1-6 (PID1094 V1.0)Study - GMMG-HD 6 - Lenalidomide 10 / Dexamethasone 12, Multiple Myeloma, Maintenance Cycle 7+ (PID1095 V1.0)Study - GMMG-HD 6 - Lenalidomide 15 / Dexamethasone 12 / Elotuzumab 10, Multiple Myeloma, Maintenance Cycle 7+ (PID1093 V1.1)Talquetamab (0.01/0.06/0.4), Multiple Myeloma, cycle 1 (PID2469 V1.0)Talquetamab (0.01/0.06/0.4/0.8), Multiple Myeloma, cycle 1 (PID2467 V1.0)Talquetamab 0.4, Multiple Myeloma, Cycle 2+ (PID2470 V1.0)Talquetamab 0.8, Multiple Myeloma, Cycle 2+ (PID2468 V1.0)Teclistamab (0.06/0.3/1.5) / Daratumumab 1800, Multiple Myeloma, Cycle 1 (PID3085 V1.0)Teclistamab (0.06/0.3/1.5) / Talquetamab (0.01/0.06/0.4), Multiple Myeloma, Cycle 1 (PID2962 V1.0)Teclistamab (0.06/0.3/1.5), Multiple Myeloma, Cycle 1 (PID2391 V1.0)Teclistamab 1.5 / Daratumumab 1800, Multiple Myeloma, Cycle 2 (PID3086 V1.0)Teclistamab 1.5, Multiple Myeloma, Cycle 2+ (PID2392 V1.0)Teclistamab 3 / Daratumumab 1800, Multiple Myeloma, Cycle 3-6 (PID3087 V1.0)Teclistamab 3 / Daratumumab 1800, Multiple Myeloma, cycle 7+ (PID3088 V1.0)Teclistamab 3 / talquetamab 0.8, multiple myeloma, cycle 2-7 (PID2963 V1.0)Teclistamab 3 / talquetamab 0.8, multiple myeloma, cycle 8+ (PID2964 V1.0)Venetoclax 800 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma, Cycle 1-8 (PID1790 V1.0)Venetoclax 800 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma, Cycle 9+ (PID1791 V1.0)Venetoclax 800 / Dexamethasone 40, Multiple Myeloma (PID2448 V1.0)Zoledronate 4, Multiple Myeloma (PID351 V2.0)
